BerGenBio ASA: Invitation to first quarter 2024 results webcast

Bergen, Norway, 22 May 2024 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will announce its results for the first quarter 2024 on Wednesday 29 May 2024.

BerGenBio's senior management team will provide a business update at 10:00 am CET. The presentation will webcast live. To participate in the webcast please use this link:


A recording of the webcast will be available at in the Investors/Financial Reports section shortly afterwards.


The first quarter financial report and presentation will also be made available on the Company’s website in the Investors/Financial Reports section from 7:00am CET the same day.





Martin Olin, CEO BerGenBio ASA 


Rune Skeie, CFO BerGenBio ASA


Media Relations

Jan Lilleby


About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.


The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit


Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.


This information is subject to the disclosure requirements pursuant to MAR article 17 and section 5-12 of the Norwegian Securities Trading Act.